On October 2, 2020, the U.S. Food and Drug Administration (FDA) approved a supplemental application for Keytruda (pembrolizumab). This approval specifically addresses the efficacy of the drug, as indicated by the sponsor MERCK SHARP DOHME.
Background
Pembrolizumab, marketed as Keytruda, is an established immunotherapy that targets the programmed death receptor-1 (PD-1) pathway. It is a monoclonal antibody that works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby releasing PD-1 pathway-mediated inhibition of the immune response and promoting anti-tumor activity. The FDA's supplemental approval process allows for updates to existing drug applications, which can include new indications, dosing regimens, or manufacturing changes. This specific supplemental approval (BLA 125514 S-70) focused on efficacy, meaning the agency reviewed data supporting the drug's effectiveness for a particular use.
What this means
The FDA's supplemental approval for Keytruda (pembrolizumab) regarding its efficacy indicates that the agency has reviewed additional data and determined that the drug demonstrates effectiveness for a new or updated aspect of its use. While the specific indication or population for this efficacy update is not detailed in the provided information, such approvals typically expand the therapeutic scope or refine the understanding of the drug's benefits for patients. This allows clinicians to consider Keytruda for an expanded or modified treatment approach based on the new efficacy data, potentially broadening its utility in patient care.
Source
The information for this update was obtained from the U.S. Food and Drug Administration (FDA) website. The supplemental application for Keytruda (pembrolizumab), identified as BLA 125514 S-70, was approved on October 2, 2020, and is publicly accessible on accessdata.fda.gov.